RADIOPHARM THERANOSTICS LTD (RADX) Stock Overview
NASDAQ:RADX - ADR
RADX Key Statistics, Chart & Performance
The current stock price of RADX is 5.5 USD. In the past month the price increased by 14.37%.
RADX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.68 | 368.08B | ||
| AMGN | AMGEN INC | 13.28 | 155.90B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.86 | 99.27B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.88 | 62.29B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.14B | ||
| ARGX | ARGENX SE - ADR | 76.39 | 43.34B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.24 | 36.72B | ||
| INSM | INSMED INC | N/A | 27.94B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.19B | ||
| NTRA | NATERA INC | N/A | 22.74B | ||
| BIIB | BIOGEN INC | 8.54 | 20.04B |
Related stock screener links
About RADX
Company Profile
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm has a pipeline of highly differentiated molecules spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumor cancers including brain, lung, breast and pancreas. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
Company Info
RADIOPHARM THERANOSTICS LTD
Level 3, 62 Lygon Street, Carlton
Melbourne VICTORIA AU
Employees: 0
Phone: 61398245254
RADIOPHARM THERANOSTICS LTD / RADX FAQ
What is the stock price of RADIOPHARM THERANOSTICS LTD today?
The current stock price of RADX is 5.5 USD. The price decreased by -1.79% in the last trading session.
What is the ticker symbol for RADIOPHARM THERANOSTICS LTD stock?
The exchange symbol of RADIOPHARM THERANOSTICS LTD is RADX and it is listed on the Nasdaq exchange.
On which exchange is RADX stock listed?
RADX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RADIOPHARM THERANOSTICS LTD stock?
7 analysts have analysed RADX and the average price target is 6.92 USD. This implies a price increase of 25.79% is expected in the next year compared to the current price of 5.5. Check the RADIOPHARM THERANOSTICS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RADIOPHARM THERANOSTICS LTD worth?
RADIOPHARM THERANOSTICS LTD (RADX) has a market capitalization of 42.79M USD. This makes RADX a Nano Cap stock.
How many employees does RADIOPHARM THERANOSTICS LTD have?
RADIOPHARM THERANOSTICS LTD (RADX) currently has 0 employees.
What are the support and resistance levels for RADIOPHARM THERANOSTICS LTD (RADX) stock?
RADIOPHARM THERANOSTICS LTD (RADX) has a support level at 5.49 and a resistance level at 5.68. Check the full technical report for a detailed analysis of RADX support and resistance levels.
Is RADIOPHARM THERANOSTICS LTD (RADX) expected to grow?
The Revenue of RADIOPHARM THERANOSTICS LTD (RADX) is expected to grow by 3017.96% in the next year. Check the estimates tab for more information on the RADX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy RADIOPHARM THERANOSTICS LTD (RADX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RADX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RADX, evaluating the profitability, health, valuation and growth aspects
- RADIOPHARM THERANOSTICS LTD (RADX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RADIOPHARM THERANOSTICS LTD (RADX) Sales and EPS estimates to see what analysts future expectations are.
- RADIOPHARM THERANOSTICS LTD (RADX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RADIOPHARM THERANOSTICS LTD (RADX) Insider and Institutional Ownership to learn about the owners and their transactions.
- RADIOPHARM THERANOSTICS LTD (RADX) Stock Chart to make your own analysis
- RADIOPHARM THERANOSTICS LTD (RADX) Latest news and press-releases to stay up to date.
Does RADIOPHARM THERANOSTICS LTD (RADX) stock pay dividends?
RADX does not pay a dividend.
What is the Price/Earnings (PE) ratio of RADIOPHARM THERANOSTICS LTD (RADX)?
RADIOPHARM THERANOSTICS LTD (RADX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.83).
What is the Short Interest ratio of RADIOPHARM THERANOSTICS LTD (RADX) stock?
The outstanding short interest for RADIOPHARM THERANOSTICS LTD (RADX) is 0.39% of its float. Check the ownership tab for more information on the RADX short interest.
RADX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RADX.
RADX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RADX. RADX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RADX Financial Highlights
Over the last trailing twelve months RADX reported a non-GAAP Earnings per Share(EPS) of -9.83. The EPS increased by 52.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.34% | ||
| ROE | -78.79% | ||
| Debt/Equity | 0 |
RADX Forecast & Estimates
7 analysts have analysed RADX and the average price target is 6.92 USD. This implies a price increase of 25.79% is expected in the next year compared to the current price of 5.5.
For the next year, analysts expect an EPS growth of 70.87% and a revenue growth 3017.96% for RADX